MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of MEM-288 in patients with advanced solid tumors. Eligible subjects must have a tumor lesion(s) which is accessible for injection. The dose escalation phase (Part 1A - advanced solid tumors) has completed and is closed to enrollment. This phase evaluated multiple doses of MEM-288 dosed via intratumoral injection once every 3 weeks to assess safety, tolerability, preliminary efficacy, and to determine the MTD. The dose expansion phase has multiple parts for advanced NSCLC. Part 1B has completed after evaluation of MEM-288 dosed via intratumoral injection in combination with standard of care nivolumab dosed via intravenous injection. In a separate dose expansion arm (Part 1C) that is open for enrollment, patients with advanced NSCLC will be randomized to receive either an initial priming dose of MEM-288 injected into an accessible lesion (s) alone (Day 1) followed by MEM-288 in combination with standard of care docetaxel every 3 weeks up to 6 doses or MEM-288 injected into an accessible lesion(s) in combination with standard of care docetaxel therapy Day 1 and every 3 weeks up to 6 doses. The study rationale is that the oncolytic effect of MEM-288 combined with the presence of CD40L and type 1 IFN in injected tumors will provide a strong signal for DC-mediated T cell activation leading to generation of systemic anti-tumor T cell responses with broad specificity akin to what is observed in the abscopal effect.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zdolność do zrozumienia i wyrażenia świadomej zgody na udział w badaniu.
- •Gotowość i możliwość uczestnictwa w zaplanowanych wizytach i procedurach badania.
- •Wiek 18 lat lub więcej.
- •Dobry stan ogólny (ECOG 0 lub 1).
- •Zaawansowany lub rozsiany nowotwór (rak płuc, rak skóry, czerniak, rak piersi, rak trzustki lub rak głowy i szyi).
- •Rak płuc, który progresował po wstępnym leczeniu lekami blokującymi PD-1/PD-L1.
- •Wcześniejsze leczenie standardowymi terapiami dla danego typu nowotworu (co najmniej jedno poprzednie leczenie).
- •W zależności od typu nowotworu: wcześniejsze leczenie chemioterapią, inhibitorami BRAF, lekami blokującymi punkty kontrolne lub innymi zatwierdzonymi terapiami.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Moffitt Cancer Center
Tampa, United States
Duke Cancer Institute
Durham, United States
Trial contact
Chairman, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.